Immune Monitoring on Sipuleucel-T
| Status: | Completed |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/5/2017 |
| Start Date: | June 2012 |
| End Date: | December 2016 |
A Systems Biology Approach to Immune Monitoring in Patients With Castration-resistant Prostate Cancer Receiving SiPuleucel-T
The purpose of this protocol is perform comprehensive immune monitoring studies in patients
with castration-resistant prostate cancer receiving Sipuleucel-T in an effort to better
understand the mechanism of action of this treatment.
with castration-resistant prostate cancer receiving Sipuleucel-T in an effort to better
understand the mechanism of action of this treatment.
The primary objectives of this study are to:
1. Establish the phenotype and frequency of circulating immune cell compartments in
patients undergoing treatment with Sipuleucel-T.
2. Determine the induction and the quality of prostate antigen-specific T cell immunity in
patients undergoing treatment with Sipuleucel-T.
3. Correlate whole-blood RNA transcript-based signatures with clinical outcomes in
patients treated with Sipuleucel-T.
4. Evaluate the cytokine and chemokine milieu in the peripheral blood pre- and
post-treatment with Sipuleucel-T.
1. Establish the phenotype and frequency of circulating immune cell compartments in
patients undergoing treatment with Sipuleucel-T.
2. Determine the induction and the quality of prostate antigen-specific T cell immunity in
patients undergoing treatment with Sipuleucel-T.
3. Correlate whole-blood RNA transcript-based signatures with clinical outcomes in
patients treated with Sipuleucel-T.
4. Evaluate the cytokine and chemokine milieu in the peripheral blood pre- and
post-treatment with Sipuleucel-T.
Inclusion Criteria:
- Age > 18 years of age
- Written informed consent obtained
- Patients with castration-resistant prostate cancer who are initiating Sipuleucel-T as
standard therapy
- No prior systemic chemotherapy for metastatic prostate cancer
- Hemoglobin > 9 mg/dl
Exclusion Criteria:
- Patients unable to understand the research protocol and/or provide informed consent
We found this trial at
3
sites
Click here to add this to my saved trials
Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai is...
Click here to add this to my saved trials
Click here to add this to my saved trials